Clinical trial
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
NCT00108953 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00108953 |
|---|---|
| Title | A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma |
| Official title | A Randomized Controlled Study of BAY43-9006 in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma. |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin, Doxorubicin/Placebo |
| Enrollment | 96 |
| Start date | Apr 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Apr 22, 2005 |
| Last update posted | Oct 31, 2014 |
| Countries | Argentina, Canada, Hong Kong, Russia, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: